Printer Friendly

Gene therapy proposal gains acceptance.

Gene therapy proposal gains acceptance

On June 1, a National Institutes of Health (NIH) subcommittee approved use of an experimental gene therapy to treat children with a severe, inherited immune disorder. The project must clear other regulatory hurdles, but federal scientists say they may begin treating three or four children with adenosine deaminase deficiency as early as this fall.

Children afflicted with this disorder lack the enzyme adenosine deaminase, a problem that results in destruction of white cells that help the body fight infection. Under the plan, scientists would engineer white cells to carry healthy genes that code for the missing enzyme (SN: 4/7/90, p.213).

NIH researchers R. Michael Blaese and W. French Anderson note that their proposal must first win the approval of another NIH review panel and the Food and Drug Administration.
COPYRIGHT 1990 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1990, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:to treat children with adenosine deaminase deficiency
Publication:Science News
Date:Jun 16, 1990
Previous Article:Foot feat: transplant treats dystrophy.
Next Article:Slicing new sulfur chemical from onion.

Related Articles
Research progress toward gene therapy.
Enzyme ruse successful.
Subcommittee okays human gene transfer.
First gene therapy in humans proposed.
Gene therapists told to do homework.
First human gene-therapy test begun.
Early results of gene therapy encouraging.
Human gene therapy wins crucial victory.
Gene therapy's up ....
"Bubble" babies thrive on gene therapy.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters